Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Up 1.6% Today

What is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ: AMLX) Market: AMLX experienced robust bullish movement today, fueled by positive market sentiment.

Why is Amylyx Pharmaceuticals going up?

AMLX stock is up 1.6% on Mar 23, 2026 15:10

• A surge in the price target and a "buy" rating by Guggenheim analyst, alongside optimistic projections from other analysts, likely boosted the stock's performance.
• Notable investment by Maven Securities LTD in AMLX and increased institutional involvement suggest mounting confidence in the company's future.
• The narrowing of losses, expanded shelf capacity, and strategic focus on advancing its pipeline at Amylyx Pharmaceuticals have likely reassured investors and garnered favorable attention, leading to the upward momentum in the stock price.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Guggenheim Analyst Says

Guggenheim has increased its price target for Amylyx Pharmaceuticals (NASDAQ:AMLX) to $30 from $25, maintaining a "buy" rating and suggesting a 117% upside. The company's average analyst rating is a "Moderate Buy" with a consensus target of $20.11, following several recent analyst reports. Amylyx recently reported quarterly EPS of -$0.30, beating estimates, and its stock is trading around $13.82.

https://www.marketbeat.com/instant-alerts/amylyx-pharmaceuticals-nasdaqamlx-stock-price-expected-to-rise-guggenheim-analyst-says-2026-03-19/

Maven Securities LTD Makes New $951,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX

Maven Securities LTD has made a new investment of $951,000 in Amylyx Pharmaceuticals (AMLX), purchasing 70,000 shares. This comes amidst significant institutional activity in AMLX, with other major firms also adjusting their positions. Amylyx Pharmaceuticals has a "Moderate Buy" consensus rating from analysts with a target price of $19.56, and recently reported an EPS of -$0.30, beating estimates.

https://www.marketbeat.com/instant-alerts/filing-maven-securities-ltd-makes-new-951000-investment-in-amylyx-pharmaceuticals-inc-amlx-2026-03-18/

How Investors May Respond To Amylyx Pharmaceuticals (AMLX) Narrowed 2025 Losses And Expanded Shelf Capacity

Amylyx Pharmaceuticals reported narrowed net losses for Q4 and full-year 2025, alongside new shelf registrations for various securities. These developments suggest increased financial flexibility for future growth, though potential shareholder dilution remains a concern. The company's investment narrative now focuses on advancing its pipeline while managing capital needs.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/how-investors-may-respond-to-amylyx-pharmaceuticals-amlx-nar

Trending Today

fuboTV Inc. ($FUBO) Stock Forecast: Down 5.1% Today

Centene Corporation ($CNC) Stock Forecast: Down 5.0% Today

Texas Roadhouse Inc. ($TXRH) Stock Forecast: Down 2.3% Today

NASDAQ-100 ($NDX) Index Forecast: Up 1.9% Today

Chegg Inc. ($CHGG) Stock Forecast: Down 3.2% Today

Micron Technology Inc. ($MU) Stock Forecast: Down 5.4% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.1% Today

Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Up 1.6% Today

Solana ($SOL) Crypto Forecast: Up 5.5% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Up 5.0% Today

Amylyx Pharmaceuticals Price History

26.01.2026 - AMLX Stock was up 5.4%

• The positive market performance of Amylyx Pharmaceuticals could be attributed to the optimistic outlook and anticipation surrounding the forthcoming financial results disclosure.
• FDA's contentious approval of the ALS drug, Relyvrio, and the challenges faced by Biogen and Ionis Pharmaceuticals in halting their ALS drug, BIIB105, may have created a conducive environment for companies like Amylyx Pharmaceuticals in the ALS treatment sector.
• Investors may be hopeful about Amylyx's prospects in the ALS market, given the pressing need for effective treatments and recent industry advancements.
• The favorable response from the market to Amylyx Pharmaceuticals could also be influenced by the company's strategic positioning and growth prospects in the field of neurodegenerative disease treatment.

12.02.2026 - AMLX Stock was down 6.5%

• The decline in AMLX stock could be connected to investors potentially feeling unimpressed by the disclosures made at a recent conference concerning the avexitide program and the company's overall pipeline expansion.
• Despite the encouraging news of the Phase 3 trial nearing completion and the forthcoming Q3 data release, market expectations may have been higher for significant advancements or milestones.
• The absence of immediate positive triggers or groundbreaking updates might have prompted traders to take profits, as they may have been anticipating a more notable market response to the company's advancements.
• Investors may be taking a profit-making strategy following the conference updates, leading to a temporary downturn in the stock price.

24.01.2026 - AMLX Stock was up 6.0%

• AMLX experienced a strong bullish movement likely due to the FDA approval of Relyvrio, a new ALS drug, despite controversies surrounding its preliminary trial data. This approval signifies potential growth opportunities for AMLX in the ALS treatment market.
• The decision by Biogen and Ionis Pharmaceuticals to shelve their ALS drug development after a study failure could have further boosted investor confidence in AMLX as it positions itself favorably in the competitive landscape.
• The setbacks in ALS drug development faced by other companies highlight the challenges in the industry, making AMLX a potentially attractive investment option for traders seeking growth in the pharmaceutical sector.

03.02.2026 - AMLX Stock was down 8.0%

• Today's bearish movement in AMLX's stock price could be attributed to the significant financial declines reported in fiscal year 2024, with revenue dropping by 77.1% and net income at a negative value.
• Insider selling activities, including a plan to sell a substantial number of shares, might have raised concerns among investors about the company's future prospects.
• Participation in upcoming investor conferences could potentially provide a platform for the company to showcase its developments, but the mixed financial signals and insider selling could have overshadowed any positive sentiment, leading to the bearish market movement.
• The automatic sale of shares by the Chief Legal Officer for tax purposes further added to the selling pressure on the stock, contributing to the overall bearish sentiment surrounding AMLX today.

10.02.2026 - AMLX Stock was up 7.7%

• The uptrend in AMLX stock today is linked to the favorable Q4 2025 earnings release that exceeded EPS projections and highlighted significant advancements in the company's pipeline.
• The Co-CEOs' sale of shares to address tax obligations, though initially raising questions, was clarified as obligatory transactions tied to RSU vesting, demonstrating confidence in the company's future outlook.
• Amylyx Pharmaceuticals' reduced net losses and the initiation of new shelf registrations have bolstered the company's financial flexibility, despite the potential for shareholder dilution, positively shaping the stock's investment story.

04.01.2026 - AMLX Stock was down 6.2%

• The Co-Chief Executive Officer selling a significant amount of AMLX shares to cover option costs and tax obligations likely raised concerns among investors, indicating lack of confidence in the stock.
• The ongoing investigations into alleged breaches of fiduciary duties by Amylyx Pharmaceuticals officers and directors could have contributed to the negative sentiment surrounding the stock.
• Shareholders being encouraged to discuss their rights and potential legal actions against the company's management might have added to the uncertainty and selling pressure on AMLX shares.
• The combination of executive selling, fiduciary duty investigations, and shareholder rights discussions could have created a perfect storm of negative news leading to the bearish movement in AMLX stock today.

04.02.2026 - AMLX Stock was up 5.5%

• AMLX reported significantly reduced losses in 2025, with a pivot towards advancing their avexitide program for post-bariatric hypoglycemia (PBH) showing promising results.
• The completion of recruitment for the pivotal Phase 3 LUCIDITY trial and the selection of new development candidates indicate positive progress in their pipeline, boosting investor confidence.
• Despite an insider, Joshua B. Cohen, planning to sell shares, the overall positive financial results and strategic advancements seem to have outweighed any potential concerns, driving the bullish market movement for AMLX today.

11.01.2026 - AMLX Stock was down 5.2%

• Positive forecasts and a raised price target did not prevent a bearish movement in the stock of Amylyx Pharmaceuticals (AMLX).
• Insider transactions, with a director buying shares and the CEO selling some, may have contributed to investor uncertainty.
• Despite strong financial health and significant cash reserves, Amylyx Pharmaceuticals is not yet profitable.
• The market's cautious response to the company's path to avexitide approval, despite a "structurally de-risked" trial design, led to the downward trend in the stock price.

23.02.2026 - AMLX Stock was up 1.6%

• A surge in the price target and a "buy" rating by Guggenheim analyst, alongside optimistic projections from other analysts, likely boosted the stock's performance.
• Notable investment by Maven Securities LTD in AMLX and increased institutional involvement suggest mounting confidence in the company's future.
• The narrowing of losses, expanded shelf capacity, and strategic focus on advancing its pipeline at Amylyx Pharmaceuticals have likely reassured investors and garnered favorable attention, leading to the upward momentum in the stock price.

27.01.2026 - AMLX Stock was up 5.4%

• Amylyx Pharmaceuticals' stock (AMLX) experienced a bullish movement due to its participation in upcoming investor conferences and potential positive outcomes from its pipeline therapies.
• The Chief Legal Officer, Gina Mazzariello, sold shares, but this did not impact investors significantly, with several analysts increasing their valuation estimates for AMLX, showing faith in the company's pipeline.
• The forthcoming announcement of financial results on March 3, 2026, added to the positive outlook on AMLX, with investors awaiting insights into the company's performance and future prospects.
• Although concerns were voiced by TipRanks' AI Analyst, Spark, about financial performance and technicals, overall market sentiment towards Amylyx Pharmaceuticals remained positive, leading to the uptrend in the stock price.

05.02.2026 - AMLX Stock was down 5.9%

• The bearish movement in AMLX today may have been influenced by the Co-CEOs selling shares to cover tax obligations related to the vesting of restricted stock units, sparking concerns about leadership confidence.
• Despite surpassing EPS expectations and showcasing progress in the pipeline with positive Q4 and full-year 2025 earnings, the impact of Co-CEOs' share sales may have outweighed the optimistic results.
• An adverse reaction from investors towards insider selling, despite the company's robust financial standing, ample cash reserves, and advancements in its drug programs.
• The market's response could also be attributed to short-term profit-taking by investors post-recent positive developments, leading to a temporary decline in the stock price.

30.00.2026 - AMLX Stock was down 5.6%

• There is an ongoing investigation regarding potential breaches of fiduciary duties by certain officers and directors of Amylyx Pharmaceuticals, which may have prompted investor concerns and a subsequent sell-off.
• While HC Wainwright offered a positive earnings estimate for FY2030, insider selling of shares and an uptick in institutional holdings could have spurred uncertainty and contributed to the downward trend.
• Analysts have given an average recommendation of "Moderate Buy" for the stock, and with the stock trading above its moving averages, mixed sentiments in the market may have led to a lack of clear direction and the ensuing decline in stock value.